---
title: "Travere Therapeutics, Inc. (TVTX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TVTX.US.md"
symbol: "TVTX.US"
name: "Travere Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T12:40:25.398Z"
locales:
  - [en](https://longbridge.com/en/quote/TVTX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TVTX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TVTX.US.md)
---

# Travere Therapeutics, Inc. (TVTX.US)

## Company Overview

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [ravere.com](https://ravere.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: C (0.48)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 81 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 96.03% |  |
| Net Profit YoY | 90.55% |  |
| P/B Ratio | 39.81 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3929880165.30 |  |
| Revenue | 536195000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -69.38% | E |
| Profit Margin | -4.00% | D |
| Gross Margin | 34.07% | C |
| Revenue YoY | 96.03% | A |
| Net Profit YoY | 90.55% | A |
| Total Assets YoY | 1.16% | C |
| Net Assets YoY | 200.79% | A |
| Cash Flow Margin | -184.91% | E |
| OCF YoY | 96.03% | A |
| Turnover | 0.97 | A |
| Gearing Ratio | 82.22% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Travere Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "96.03%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "90.55%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "39.81",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3929880165.30",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "536195000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-69.38%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-4.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "34.07%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "96.03%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "90.55%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "1.16%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "200.79%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-184.91%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "96.03%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.97",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "82.22%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -183.45 | 548/386 | - | - | - |
| PB | 39.81 | 431/386 | 48.21 | 41.81 | 33.90 |
| PS (TTM) | 7.33 | 144/386 | 7.34 | 6.04 | 5.02 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **15**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 12 | 80% |
| Overweight | 2 | 13% |
| Hold | 1 | 7% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 42.26 |
| Highest Target | 56.00 |
| Lowest Target | 40.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/TVTX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/TVTX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/TVTX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/TVTX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**